Published in Cell Cycle on February 06, 2017
Cancer Statistics, 2017. CA Cancer J Clin (2017) 4.77
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 4.60
Characterization of two genes required for the position-effect control of yeast mating-type genes. EMBO J (1984) 3.30
The emerging and diverse roles of sirtuins in cancer: a clinical perspective. Onco Targets Ther (2013) 1.57
Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 1.33
Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem Biophys Res Commun (2009) 1.15
SIRT1 deacetylase is overexpressed in human melanoma and its small molecule inhibition imparts anti-proliferative response via p53 activation. Arch Biochem Biophys (2014) 0.98
Genealogy of an ancient protein family: the Sirtuins, a family of disordered members. BMC Evol Biol (2013) 0.88
Novel downstream molecular targets of SIRT1 in melanoma: a quantitative proteomics approach. Oncotarget (2014) 0.87
A chromatin modifier genetic screen identifies SIRT2 as a modulator of response to targeted therapies through the regulation of MEK kinase activity. Oncogene (2014) 0.83
Sirtuin deacetylases: a new target for melanoma management. Cell Cycle (2014) 0.82
Managing the skin toxicities from new melanoma drugs. Curr Treat Options Oncol (2014) 0.82
Biology, Chemistry, and Pharmacology of Sirtuins. Methods Enzymol (2016) 0.82
Profile of vemurafenib-induced severe skin toxicities. J Eur Acad Dermatol Venereol (2015) 0.81
SIRT2 Expression Is Higher in Uveal Melanoma than In Ocular Melanocytes. Ocul Oncol Pathol (2015) 0.79